JP2017523790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523790A5 JP2017523790A5 JP2017506667A JP2017506667A JP2017523790A5 JP 2017523790 A5 JP2017523790 A5 JP 2017523790A5 JP 2017506667 A JP2017506667 A JP 2017506667A JP 2017506667 A JP2017506667 A JP 2017506667A JP 2017523790 A5 JP2017523790 A5 JP 2017523790A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- subject
- diabetes
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 8
- 239000002777 nucleoside Substances 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 4
- 238000010276 construction Methods 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000010706 fatty liver disease Diseases 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034739P | 2014-08-07 | 2014-08-07 | |
| US62/034,739 | 2014-08-07 | ||
| US201462062749P | 2014-10-10 | 2014-10-10 | |
| US62/062,749 | 2014-10-10 | ||
| US201562143434P | 2015-04-06 | 2015-04-06 | |
| US62/143,434 | 2015-04-06 | ||
| PCT/US2015/043926 WO2016022753A1 (en) | 2014-08-07 | 2015-08-06 | Targeting micrornas for metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523790A JP2017523790A (ja) | 2017-08-24 |
| JP2017523790A5 true JP2017523790A5 (enExample) | 2018-09-06 |
Family
ID=53836884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506667A Ceased JP2017523790A (ja) | 2014-08-07 | 2015-08-06 | 代謝障害のためのマイクロｒｎａの標的化 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9487783B2 (enExample) |
| EP (1) | EP3177721A1 (enExample) |
| JP (1) | JP2017523790A (enExample) |
| KR (1) | KR20170033439A (enExample) |
| CN (1) | CN106559995A (enExample) |
| AU (1) | AU2015301057A1 (enExample) |
| BR (1) | BR112017001931A2 (enExample) |
| CA (1) | CA2953883A1 (enExample) |
| CL (1) | CL2017000312A1 (enExample) |
| CO (1) | CO2017000950A2 (enExample) |
| IL (1) | IL249819A0 (enExample) |
| MA (1) | MA40463A (enExample) |
| MX (1) | MX2017001493A (enExample) |
| RU (1) | RU2017105342A (enExample) |
| SG (1) | SG11201610877PA (enExample) |
| TW (1) | TW201613949A (enExample) |
| WO (1) | WO2016022753A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
| AU2017260003B2 (en) * | 2016-05-06 | 2019-12-05 | Astrazeneca Ab | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| KR101869308B1 (ko) * | 2017-02-28 | 2018-06-20 | 대구가톨릭대학교산학협력단 | Srebp-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물 |
| EA202091533A1 (ru) | 2018-01-17 | 2020-11-16 | Юниверсити Оф Коннектикут | Способы лечения диабета, гепатита и/или воспалительного заболевания печени |
| US11690804B2 (en) * | 2018-07-02 | 2023-07-04 | Aptamir Therapeutics, Inc. | Targeted delivery of therapeutic agents to human adipocytes |
| JP2021531278A (ja) * | 2018-07-20 | 2021-11-18 | レグルス セラピューティクス インコーポレイテッド | オリゴヌクレオチドの経口送達のための方法 |
| US10844383B1 (en) | 2019-09-18 | 2020-11-24 | Dasman Diabetes Institute | Microrna dyslipidemia inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862439A4 (en) | 1995-11-22 | 2001-01-10 | O Paul O P Ts | LIGANDS FOR INCREASING THE CELLULAR UPtake OF BIOMOLECULES |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | Ｎ−ｏ結合性架橋構造型新規人工核酸 |
| EP1768998A2 (en) | 2004-04-27 | 2007-04-04 | Alnylam Pharmaceuticals Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| CA2576233C (en) | 2004-08-10 | 2016-03-15 | Alnylam Pharmaceuticals, Inc. | Conjugate comprising an antagomir and a ligand |
| EP2302053A1 (en) | 2004-11-12 | 2011-03-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| EP2338992A3 (en) | 2005-08-29 | 2011-10-12 | Regulus Therapeutics, Inc | Antisense compounds having enhanced anti-microRNA activity |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| AU2007234191B2 (en) | 2006-04-03 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides |
| ES2611924T3 (es) | 2006-10-03 | 2017-05-11 | Arbutus Biopharma Corporation | Formulaciones que contienen lípidos |
| CN101121934B (zh) | 2007-04-11 | 2011-12-07 | 哈尔滨医科大学 | 多靶点miRNA反义核苷酸的制备方法 |
| AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| MY156951A (en) | 2007-10-04 | 2016-04-15 | Santaris Pharma As | Micromirs |
| AU2008340355B2 (en) | 2007-12-04 | 2015-01-22 | Tekmira Pharmaceuticals Corporation | Targeting lipids |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| EP2432880A1 (en) * | 2009-05-20 | 2012-03-28 | ETH Zürich | Targeting micrornas for metabolic disorders |
| GEP20156329B (en) | 2009-06-08 | 2015-07-27 | Miragen Therapeutics | CHEMICAL MODIFICATIONS OF miRNA INHIBITORS AND MIMETICS |
| ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| US20130079505A1 (en) * | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| CA2816155C (en) | 2010-12-17 | 2020-10-27 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| US8877722B2 (en) | 2011-03-25 | 2014-11-04 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting gene expression and uses thereof |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP3533873A1 (en) * | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
| WO2013133221A1 (ja) | 2012-03-04 | 2013-09-12 | 株式会社ボナック | microRNA阻害剤 |
| KR101928418B1 (ko) | 2012-06-21 | 2018-12-12 | 미라젠 세러퓨틱스 인코포레이티드 | 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제 |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| JP2015529469A (ja) | 2012-09-14 | 2015-10-08 | ラナ セラピューティクス インコーポレイテッド | 多量体オリゴヌクレオチド化合物 |
| US9725721B2 (en) | 2012-09-26 | 2017-08-08 | Mirrx Therapeutics | Oligomers with improved off-target profile |
| WO2014076196A1 (en) * | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| RU2670614C9 (ru) | 2013-05-01 | 2018-11-23 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии hbv и ttr |
| WO2014179445A1 (en) | 2013-05-01 | 2014-11-06 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
-
2015
- 2015-08-06 US US14/819,648 patent/US9487783B2/en not_active Expired - Fee Related
- 2015-08-06 CA CA2953883A patent/CA2953883A1/en not_active Abandoned
- 2015-08-06 WO PCT/US2015/043926 patent/WO2016022753A1/en not_active Ceased
- 2015-08-06 AU AU2015301057A patent/AU2015301057A1/en not_active Abandoned
- 2015-08-06 KR KR1020177005873A patent/KR20170033439A/ko not_active Withdrawn
- 2015-08-06 TW TW104125684A patent/TW201613949A/zh unknown
- 2015-08-06 RU RU2017105342A patent/RU2017105342A/ru not_active Application Discontinuation
- 2015-08-06 SG SG11201610877PA patent/SG11201610877PA/en unknown
- 2015-08-06 CN CN201580039229.9A patent/CN106559995A/zh active Pending
- 2015-08-06 MX MX2017001493A patent/MX2017001493A/es unknown
- 2015-08-06 JP JP2017506667A patent/JP2017523790A/ja not_active Ceased
- 2015-08-06 EP EP15750573.6A patent/EP3177721A1/en not_active Withdrawn
- 2015-08-06 BR BR112017001931A patent/BR112017001931A2/pt not_active Application Discontinuation
- 2015-08-06 MA MA040463A patent/MA40463A/fr unknown
-
2016
- 2016-09-22 US US15/272,619 patent/US9862950B2/en not_active Expired - Fee Related
- 2016-12-28 IL IL249819A patent/IL249819A0/en unknown
-
2017
- 2017-02-01 CO CONC2017/0000950A patent/CO2017000950A2/es unknown
- 2017-02-07 CL CL2017000312A patent/CL2017000312A1/es unknown
- 2017-10-05 US US15/725,843 patent/US10138484B2/en not_active Expired - Fee Related
-
2018
- 2018-09-25 US US16/140,881 patent/US20190153444A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523790A5 (enExample) | ||
| JP2016041733A5 (enExample) | ||
| JP2019511491A5 (enExample) | ||
| JP2018510621A5 (enExample) | ||
| JP2017505116A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| Ibanez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP2017515854A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2013537423A5 (enExample) | ||
| JP2016515124A5 (enExample) | ||
| JP2013518815A5 (enExample) | ||
| JP2019513751A5 (enExample) | ||
| JP2012521217A5 (enExample) | ||
| JP2012070740A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| JP2014513954A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2012525393A5 (enExample) |